BR112023000503A2 - Peptídeo com atividade neutralizante contra a síndrome respiratória aguda grave do coronavírus-2 - Google Patents

Peptídeo com atividade neutralizante contra a síndrome respiratória aguda grave do coronavírus-2

Info

Publication number
BR112023000503A2
BR112023000503A2 BR112023000503A BR112023000503A BR112023000503A2 BR 112023000503 A2 BR112023000503 A2 BR 112023000503A2 BR 112023000503 A BR112023000503 A BR 112023000503A BR 112023000503 A BR112023000503 A BR 112023000503A BR 112023000503 A2 BR112023000503 A2 BR 112023000503A2
Authority
BR
Brazil
Prior art keywords
peptide
acute respiratory
respiratory syndrome
severe acute
activity against
Prior art date
Application number
BR112023000503A
Other languages
English (en)
Inventor
Ji Chung Yong
Mi Kim Eun
Ji Lee Eung
Min Lee Young
A Kang Han
Kyeong Jeong Min
Original Assignee
Caregen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210030604A external-priority patent/KR102380735B1/ko
Application filed by Caregen Co Ltd filed Critical Caregen Co Ltd
Publication of BR112023000503A2 publication Critical patent/BR112023000503A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PEPTÍDEO COM ATIVIDADE NEUTRALIZANTE CONTRA A SÍNDROME RESPIRATÓRIA AGUDA GRAVE DO CORONAVÍRUS-2. A presente invenção refere-se a um peptídeo que reconhece especificamente uma proteína do coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) ou parte da mesma; uma composição para a prevenção ou tratamento de SARS-CoV-2, compreendendo o peptídeo; e uma composição para a detecção de SARS-CoV-2, compreendendo o peptídeo.
BR112023000503A 2020-07-16 2021-07-15 Peptídeo com atividade neutralizante contra a síndrome respiratória aguda grave do coronavírus-2 BR112023000503A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200088076 2020-07-16
KR1020210030604A KR102380735B1 (ko) 2020-07-16 2021-03-09 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드
PCT/KR2021/009080 WO2022015069A1 (ko) 2020-07-16 2021-07-15 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드

Publications (1)

Publication Number Publication Date
BR112023000503A2 true BR112023000503A2 (pt) 2023-01-31

Family

ID=79555716

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000503A BR112023000503A2 (pt) 2020-07-16 2021-07-15 Peptídeo com atividade neutralizante contra a síndrome respiratória aguda grave do coronavírus-2

Country Status (7)

Country Link
US (1) US20240051993A1 (pt)
EP (1) EP4183793A4 (pt)
JP (1) JP7516652B2 (pt)
KR (3) KR102628158B1 (pt)
BR (1) BR112023000503A2 (pt)
MX (1) MX2023000267A (pt)
WO (1) WO2022015069A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230141227A (ko) * 2022-03-31 2023-10-10 (주)케어젠 항염증 및 항섬유화 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0139159B1 (ko) * 1994-10-20 1998-06-01 김광호 포커스서보제어장치
MX2007009512A (es) 2005-02-08 2008-02-21 New York Blood Ct Inc Neutralizacion de anticuerpos monoclonales contra coronavirus asociado con sindrome respiratorio agudo severo.
KR101381337B1 (ko) * 2005-07-26 2014-04-11 씨엠에스 펩티드 패턴트 홀딩 컴퍼니 리미티드 신규한 생물학적 활성 펩티드 및 그의 신규한 용도
US20070160981A1 (en) * 2005-10-24 2007-07-12 Xin Chen Viral protease
JP2009537143A (ja) * 2006-05-19 2009-10-29 アムゲン インコーポレイティッド Ｓａｒｓコロナウイルスに対する抗体
KR20080012449A (ko) * 2006-08-03 2008-02-12 재단법인서울대학교산학협력재단 뉴클레오캡시드 또는 스파이크 단백질을 이용한 사스진단방법
EP2360173B1 (en) 2008-11-28 2016-01-13 NOF Corporation Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof
KR101510742B1 (ko) 2013-05-13 2015-04-10 (주)케어젠 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도
NZ715203A (en) * 2013-05-16 2019-07-26 Agency Science Tech & Res Heparan sulphates
KR101831887B1 (ko) * 2016-03-09 2018-02-27 (주)케어젠 발모 촉진 활성 및 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
KR101895228B1 (ko) * 2017-08-23 2018-10-30 대한민국 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
KR101916899B1 (ko) * 2017-08-31 2018-11-08 한국생명공학연구원 Sars 관련 코로나바이러스 및 mers 관련 코로나바이러스 동시 검출용 프라이머 및 이를 이용한 검출 방법
KR102019008B1 (ko) 2019-01-31 2019-09-05 대한민국(관리부서 질병관리본부장) 메르스 코로나바이러스 뉴클레오캡시드 융합 단백질을 이용한 메르스 코로나바이러스 검출 방법

Also Published As

Publication number Publication date
US20240051993A1 (en) 2024-02-15
KR20220009926A (ko) 2022-01-25
MX2023000267A (es) 2023-02-13
EP4183793A1 (en) 2023-05-24
KR102621336B1 (ko) 2024-01-08
JP7516652B2 (ja) 2024-07-16
KR102628159B1 (ko) 2024-01-24
WO2022015069A1 (ko) 2022-01-20
JP2023534947A (ja) 2023-08-15
KR102628158B1 (ko) 2024-01-24
KR20220009925A (ko) 2022-01-25
EP4183793A4 (en) 2024-05-22
KR20220009924A (ko) 2022-01-25

Similar Documents

Publication Publication Date Title
BR112023025360A2 (pt) Uso de um inibidor de metionina adenosiltransferase ii alfa (mat2a) e de um inibidor da proteína arginina metiltransferase tipo ii (prmt tipo ii), uso de um composto a, produtos de combinação e inibidores de mat2a
BR102021005055A2 (pt) detecção de anticorpos para sarsr-cov
BR0213817A (pt) Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
BR112023000503A2 (pt) Peptídeo com atividade neutralizante contra a síndrome respiratória aguda grave do coronavírus-2
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina
BR112022021381A2 (pt) Compostos para o tratamento de sars
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112022024662A2 (pt) Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
MX2024005839A (es) Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos.
CO2022000270A2 (es) Inhibidores de enzimas
BR112022004036A2 (pt) Comprimido mastigável palatável
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
BR112022023187A2 (pt) Compostos para o tratamento da sars
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
BR112022019685A2 (pt) Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
BR102020023578A8 (pt) Composições e métodos para tratamento do olho
BR112022019090A2 (pt) Inibidores de c5a para o tratamento de infecção por coronavírus
BR112021004464A8 (pt) composição de ração animal e uso da mesma
BR112019024707A2 (pt) terapias antissenso para tratamento de câncer